Trial Profile
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in elderly AML
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms HOVON-103-AML-Lenalidomide
- 01 May 2021 Results of translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort (n=40), published in the Annals of Hematology.
- 03 Mar 2012 Planned number of patients changed from 200 to 240 as reported by European Clinical Trials Database.
- 03 Mar 2012 Planned end date changed from 15 Sep 2012 to 13 Oct 2012 as reported by European Clinical Trials Database.